Reporting from ASCO 2022 Annual Meeting in Chicago, Georgina Long features the metastasis-free survival data from KEYNOTE-716 testing the benefit of adjuvant pembrolizumab vs placebo in stage IIB or IIC melanoma. She also explains the results from the NeoTrio study in resectable BRAF-mutated stage III melanoma with anti-PD1 therapy alone, in sequence with or concurrent with BRAF targeted therapy.
Video Reports
Dr. Tawbi on the Safety of Relatlimab Plus Nivolumab in Melanoma
Hussein A. Tawbi, MD, PhD, director, Melanoma Clinical Research and Early Drug Development and Personalized Cancer Therapy, deputy chair and professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of relatlimab plus nivolumab (Opdualag) in patients with metastatic or unresectable melanoma, according to data from the phase 2/3 RELATIVITY-047 trial (NCT03470922).
First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: BRAF/MEK Inhibitors
Experts discuss the use of BRAF and MEK inhibitors as first-line treatments for patients with metastatic melanoma.
Dr. Eroglu on the Utilization of ctDNA in Melanoma
Zeynep Eroglu, MD, medical oncologist, Department of Cutaneous Oncology, Moffitt Cancer Center, assistant professor, Department of Oncologic Sciences, the University of South Florida, Morsani College of Medicine, discusses the utilization of circulating tumor DNA (ctDNA) in patients with melanoma.